Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 87

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 87
---
 of the transactions agreed to by the parties in negotiating the Business Combination Agreement, which consists of an implied enterprise value for OmnigenicsAI (prior to the proposed Business Combination) of approximately $300,000,000. In determining whether the enterprise value described above represents the fair market value of the Company, the APx Board considered all of the factors described in the section of the proxy statement/prospectus entitled “ APx Board’s Reasons for the Approval of the Business Combination” and the fact that the purchase price for these businesses was the result of an arm’s length negotiation. As a result, the APx Board concluded that the fair market value of the Company was significantly in excess of 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account). Sources and Uses of Funds for the Business Combination The following table summarizes the sources and uses for funding the Business Combination. Where actual amounts are not known or knowable, the figures below represent APx’s good faith estimate of such amounts.

| Sources                                                    |     | Assuming          
 no                
 redemptions       
 (in U.S. dollars) |            |      |     | Assuming    
 25%         
 redemptions |            |      |     | Assuming    
 50%         
 redemptions |            |      |     | Assuming    
 75%         
 redemptions |            |      |     | Assuming    
 maximum     
 redemptions |            |      |
|:-----------------------------------------------------------|:----|:------------------|-----------:|:-----|:----|:------------|-----------:|:-----|:----|:------------|-----------:|:-----|:----|:------------|-----------:|:-----|:----|:------------|-----------:|:-----|
| Cash from Trust Account and Accrued Interest Receivable(1) |     | $                 |  6,268,825 | ​(4) |     | $           |  4,701,619 | ​(5) |     | $           |  3,134,413 | ​(6) |     | $           |  1,567,206 | ​(7) |     | $           |          — | ​(8) |
| OmnigenicsAI cash and cash equivalents(2)                  |     | $                 |      4,638 |      |     | $           |      4,638 |      |     |